P
Pierre Sié
Researcher at University of Toulouse
Publications - 86
Citations - 2900
Pierre Sié is an academic researcher from University of Toulouse. The author has contributed to research in topics: Platelet & Platelet activation. The author has an hindex of 27, co-authored 84 publications receiving 2524 citations. Previous affiliations of Pierre Sié include French Institute of Health and Medical Research & Paul Sabatier University.
Papers
More filters
Journal ArticleDOI
Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
Gilles Pernod,P. Albaladejo,Anne Godier,Charles Marc Samama,Sophie Susen,Yves Gruel,Normand Blais,Pierre Fontana,Ariel Cohen,Juan V. Llau,Nadia Rosencher,Jean-François Schved,Emmanuel de Maistre,Meyer Michel Samama,Patrick Mismetti,Pierre Sié +15 more
TL;DR: For urgent surgery with haemorrhagic risk, the drug plasma concentration should be less or equal to 30ng/mL for dabigatran and rivaroxaban and the administration of a procoagulant drug is discussed according to the NOAC concentration and the possibilities of mechanical haemostasis.
Journal ArticleDOI
Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions
Marie Levade,Elodie David,Cédric Garcia,Pierre-Alexandre Laurent,Sarah Cadot,Anne-Sophie Michallet,Jean-Claude Bordet,Constantine S. Tam,Pierre Sié,Loic Ysebaert,Bernard Payrastre +10 more
TL;DR: It is demonstrated that ibrutinib selectively inhibits platelet signaling and functions downstream of the collagen receptor glycoprotein VI and strongly affects firm platelet adhesion on von Willebrand factor (VWF) under arterial flow.
Journal ArticleDOI
Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis.
Pierre Sié,Charles Marc Samama,A. Godier,Nadia Rosencher,Annick Steib,Juan V. Llau,Philippe Van der Linden,Gilles Pernod,Thomas Lecompte,Isabelle Gouin-Thibault,Pierre Albaladejo +10 more
TL;DR: Direct oral anticoagulants--inhibitors of thrombin or factor-Xa--are expected to replace vitamin K antagonists in most of their indications and perioperative management for optimal safety regarding the risk of bleeding and thrombosis is proposed.
Journal ArticleDOI
French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding)
TL;DR: The present report from several French medical societies in the field and the French National Authority for Health provides an expert consensus for the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding).
Journal ArticleDOI
The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo.
Marie-Pierre Gratacap,Valérie Martin,Marie-Cécile Valéra,Sophie Allart,Cédric Garcia,Pierre Sié,Christian Recher,Bernard Payrastre +7 more
TL;DR: Dasatinib efficiently prevents platelet activation mediated by FcgammaRIIA cross-linking and by sera from patients with heparin-induced thrombocytopenia, suggesting that reversible antiplatelet agents acting as ATP-competitive inhibitors of SFKs may be of therapeutic interest in the treatment of this pathology.